Tirzepatide(60 mg)
Dual GIP/GLP-1 receptor agonist studied for appetite control, glucose response, and body-weight management in non-clinical research applications.
Mechanism of action
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Published literature describes its activity at both incretin receptors and effects on glucose-dependent insulin secretion, gastric emptying, and food-intake regulation in research and clinical settings.
Tirzepatide activates two gut-hormone receptors at the same time — the same signals your body normally sends after a meal to release insulin, slow digestion, and reduce appetite. Doing both together produced larger effects in studies than activating either one alone.
Research areas
- · How the brain decides you're full
- · How gut hormones tell the pancreas to release insulin
- · How fat and lean mass change over time
History & discovery
Discovered at Eli Lilly and first described in the early 2010s, tirzepatide became the first commercially studied dual GIP/GLP-1 agonist. Major clinical trials (SURPASS and SURMOUNT series) began publishing in 2021–2022.
Reconstitution & handling
Lyophilized peptides are typically reconstituted with bacteriostatic water and stored refrigerated after reconstitution. Use the dosing calculator to work out concentrations for your research preparation.
Open reconstitution calculatorAssay & QC notes
Each lot is tested by reversed-phase HPLC for purity, confirmed by mass spectrometry for identity, and screened for endotoxin contamination.